Literature DB >> 34245090

Thromboelastometry assessment of hemostatic properties in various murine models with coagulopathy and the effect of factor VIII therapeutics.

Jocelyn A Schroeder1,2,3,4, Erin A Kuether1,2,3,4, Juan Fang2,4, Weiqing Jing1, Hartmut Weiler1, David A Wilcox2,3,4, Robert R Montgomery1,2,3,4, Qizhen Shi1,2,3,4.   

Abstract

BACKGROUND: Rotational thromboelastometry (ROTEM) has been commonly used to assess the viscoelastic properties of the blood clotting process in the clinic for patients with a hemostatic or prothrombotic disorder.
OBJECTIVE: To evaluate the capability of ROTEM in assessing hemostatic properties in whole blood from various mouse models with genetic bleeding or clotting disease and the effect of factor VIII (FVIII) therapeutics in FVIIInull mice.
METHODS: Mice with a genetic deficiency in either a coagulation factor or a platelet glycoprotein were used in this study. The properties of platelet- or plasma-FVIII were also assessed. Citrated blood from mice was recalcified and used for ROTEM analysis.
RESULTS: We found that blood collected from the vena cava could generate reliable results from ROTEM analysis, but not blood collected from the tail vein, retro-orbital plexus, or submandibular vein. Age and sex did not significantly affect the hemostatic properties determined by ROTEM analysis. Clotting time (CT) and clot formation time (CFT) were significantly prolonged in FVIIInull (5- and 9-fold, respectively) and FIXnull (4- and 5.7-fold, respectively) mice compared to wild-type (WT)-C57BL/6J mice. Platelet glycoprotein (GP)IIIanull mice had significantly prolonged CFT (8.4-fold) compared to WT-C57BL/6J mice. CT and CFT in factor V (FV) Leiden mice were significantly shortened with an increased α-angle compared to WT-C57BL/6J mice. Using ROTEM analysis, we showed that FVIII expressed in platelets or infused into whole blood restored hemostasis of FVIIInull mice in a dose-dependent manner.
CONCLUSION: ROTEM is a reliable and sensitive assay for assessing therapeutics on hemostatic properties in mouse models with a bleeding or clotting disorder.
© 2021 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  bleeding; clotting; mouse model; rotational thromboelastometry

Mesh:

Substances:

Year:  2021        PMID: 34245090      PMCID: PMC8865566          DOI: 10.1111/jth.15456

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   16.036


  40 in total

1.  Thrombelastography. Present and future perspectives in clinical practice.

Authors:  P Di Benedetto; M Baciarello; L Cabetti; M Martucci; A Chiaschi; L Bertini
Journal:  Minerva Anestesiol       Date:  2003-06       Impact factor: 3.051

2.  Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis.

Authors:  S Kanaji; S A Fahs; Q Shi; S L Haberichter; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

3.  Thromboelastography: a reliable test?

Authors:  S Vig; A Chitolie; D H Bevan; A Halliday; J Dormandy
Journal:  Blood Coagul Fibrinolysis       Date:  2001-10       Impact factor: 1.276

4.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

Authors:  L Bi; A M Lawler; S E Antonarakis; K A High; J D Gearhart; H H Kazazian
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

5.  In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.

Authors:  J A Schroeder; Y Chen; J Fang; D A Wilcox; Q Shi
Journal:  J Thromb Haemost       Date:  2014-07-17       Impact factor: 5.824

6.  Nonactivated thromboelastometry able to detect fibrinolysis in contrast to activated methods (EXTEM, INTEM) in a bleeding patient.

Authors:  Miroslav Durila
Journal:  Blood Coagul Fibrinolysis       Date:  2016-10       Impact factor: 1.276

7.  The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.

Authors:  Yingyu Chen; Jocelyn A Schroeder; Juan Chen; Xiaofeng Luo; Christina K Baumgartner; Robert R Montgomery; Jianda Hu; Qizhen Shi
Journal:  Blood       Date:  2015-12-14       Impact factor: 22.113

8.  Perioperative ROTEM and ROTEMplatelet monitoring in a case of Glanzmann's thrombasthenia.

Authors:  Alberto Grassetto; Giorgio Fullin; Francesco Lazzari; Fabio Panizzo; Francesca Polese; Gianluca Gessoni; Antonio Farnia
Journal:  Blood Coagul Fibrinolysis       Date:  2017-01       Impact factor: 1.276

9.  Coagulation phenotype of wild-type mice on different genetic backgrounds.

Authors:  Alexandra Kopić; Karima Benamara; Maria Schuster; Peter Leidenmühler; Alexander Bauer; Helmut Glantschnig; Werner Höllriegl
Journal:  Lab Anim       Date:  2018-11-12       Impact factor: 2.471

10.  FIBTEM Improves the Sensitivity of Hyperfibrinolysis Detection in Severe Trauma Patients: A Retrospective Study Using Thromboelastometry.

Authors:  Il-Jae Wang; Sung-Wook Park; Byung-Kwan Bae; Sung-Hwa Lee; Hyuk Jin Choi; Sung Jin Park; Tae Young Ahn; Tae Sik Goh; Min Jee Lee; Seok Ran Yeom
Journal:  Sci Rep       Date:  2020-04-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.